Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: A single-institution experience

Leukemia and Lymphoma

Volumn 51, Issue 12, 2010, Pages 2208-2214

  Lin, Han Nan ^a   Liu, Chun Yu ^a,b   Hong, Ying Chung ^a,b   Pai, Jih Tung ^a,b   Yang, Ching Fen ^a,b   Yu, Yuan Bin ^a,b   Hsiao, Liang Tsai ^a,b   Chiou, Tzeon Jye ^a,b   Liu, Jin Hwang ^a,b   Gau, Jyh Pyng ^a,b   Tzeng, Cheng Hwai ^a,b   Chen, Po Min ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Angioimmunoblastic T cell lymphoma; peripheral T cell lymphoma; survival; Taiwan

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; MALE; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOCIAL STATUS; TAIWAN; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOBLASTIC LYMPHADENOPATHY; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 78650057944     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.525270     Document Type: Article

References (40)

1. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkins lymphomas. Blood 1998;92:76-82.
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkins Lymphoma. The Non- Hodgkins Lymphoma Classification Project. Blood 1997;89:3909-3918.
3. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-4130.
4. Mourad N, Mounier N, Briere J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe dEtude des Lymphomes de lAdulte (GELA) trials. Blood 2008;111: 4463-4470.
5. Glauco F, Edgar MM, Henry R. Angio-immunoblastic lymphadenopathy: diagnosis and clinical course. Am J Med 1975;59:803-818.
6. Martel P, Laroche L, Courville P, et al. Cutaneous involvement in patients with angioimmunoblastic lymphadenopathy with dysproteinemia: a clinical, immunohistological, and molecular analysis. Arch Dermatol 2000;136: 881-886.
7. Bradley SL, Dines DE, Banks PM, Hill RW. The lung in immunoblastic lymphadenopathy. Chest 1981;80:312-318.
8. Cho Y-U, Chi H-S, Park C-J, Jang S, Seo E-J, Huh J. Distinct features of angioimmunoblastic T-cell lymphoma with bone marrow involvement. Am J Clin Pathol 2009;131: 640-646.
9. Oka K, Nagayama R, Yatabe Y, Iijima S, Mori N. Angioimmunoblastic T-cell lymphoma with autoimmune thrombocytopenia: a report of two cases. Pathol Res Pract 2010;206:270-275.
10. Notas G, Xylouri I, Kritikos H, Stavroulaki E, Roditakis G, Boumpas D. A rare case of angioimmunoblastic T-cell lymphoma presenting with fever and late polyarthritis. Rheumatology 2009;48:859-860.
11. Siegert W, Nerl C, Agthe A, et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol 1995;6:659-664.
12. Aozasa K, Ohsawa M, Fujita MQ, et al. Angioimmunoblastic lymphadenopathy. Review of 44 patients with emphasis on prognostic behavior. Cancer 1989;63:1625-1629.
13. Chen W-L, Tsai W-C, Chao T-Y, et al. The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. Ann Hematol 2010;89:553-562.
14. Anderson JR, Armitage JO, Weisenburger DD; Non-Hodgkins Lymphoma Classification Project. Epidemiology of the non-Hodgkins lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 1998;9:717-720.
15. Kadin ME, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries: proceedings of the United States-Japan seminar, September 6 and 7, 1982, in Seattle, Washington. Hum Pathol 1983;14:745-772.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkins lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
17. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.
18. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
20. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-2479.
21. Maegawa ROB, Hussain S, Danila DC, Teruya-Feldstein J, Maki RG, OConnor OA. Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings. Leuk Lymphoma 2007;48:2071-2074.
22. de Leval L, Gisselbrecht C, Gaulard P. Advances in the understanding and management of angioimmunoblastic Tcell lymphoma. Br J Haematol 2010;148:673-689.
23. Au W-Y, Ma S-Y, Chim C-S, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005;16:206-214.
24. Pangalis GA, Moran EM, Nathwani BN, Zelman RJ, Kim H, Rappaport H. Angioimmunoblastic lymphadenopathy longterm follow-up study. Cancer 1983;52:318-321.
25. Archimbaud E, Coiffier B, Bryon PA, Vasselon C, Brizard CP, Viala JJ. Prognostic factors in angioimmunoblastic lymphadenopathy. Cancer 1987;59:208-212.
26. Lee S-S, Rüdiger T, Odenwald T, Roth S, Starostik P, Mü ller-Hermelink HK. Angioimmunoblastic T cell lymphoma is derived from mature T-helper cells with varying expression and loss of detectable CD4. Int J Cancer 2003;103:12-20.
27. Lee Y, Lee K-W, Kim J-H, et al. Epstein-Barr virus-positivity in tumor has no correlation with the clinical outcomes of patients with angioimmunoblastic T-cell lymphoma. Korean J Intern Med 2008;23:30-36.
28. Advani R, Horwitz S, Zelenetz A, Horning SJ. Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine. Leuk Lymphoma 2007;48:521-525.
29. Advani R, Warnke R, Sikic BI, Horning S. Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol 1997;8:601-603.
30. Dunleavy K, Wilson WH. Angioimmunoblastic T-cell lymphoma: immune modulation as a therapeutic strategy. Leuk Lymphoma 2007;48:449-451.
31. Ong S, Koeppen H, Larson R, Olopade O. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with fludarabine. Blood 1996;88:2354-2355.
32. Aguiar Bujanda D. Complete response of relapsed angioimmunoblastic T-cell lymphoma following therapy with bevacizumab. Ann Oncol 2008;19:396-397.
33. Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab. Leukemia 2005;19: 1993-1995.
34. Ramasamy K, Lim Z, Pagliuca A, Salisbury JR, Mufti G, Devereux S. et al. Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone. Haematologica 2006;91(Suppl.):ECR44.
35. Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath- 1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
36. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Blood Blood;2010 Jul 21. [Epub ahead of print].
37. Schetelig J, Fetscher S, Reichle A, et al. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88: 1272-1278.
38. Kyriakou C, Canals C, Goldstone A, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218-224.
39. Numata A, Miyamoto T, Ohno Y, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant 2010;45: 311-316.
40. Kyriakou C, Canals C, Finke J, et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009;27:3951-3958.